Physician profile
Nicholas A Ramey
NPI 1104008226
$15,643.04
in general payments reported to CMS, 2019-2025
17 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.42 · 2020: $97.11 · 2021: $11K · 2022: $725 · 2023: $419 · 2024: $2,769 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,679 · Food and Beverage: $1,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,678.50 |
| Food and Beverage | $1,011.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $11,411.21 | 2020-2023 | Tepezza |
| Glaukos Corporation | $2,678.50 | 2023-2024 | Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3, Kxl System (Not Refurbished) |
| Merz Pharmaceuticals, LLC | $282.05 | 2021-2025 | Xeomin |
| Amgen INC. | $276.88 | 2024-2025 | Tepezza |
| Allergan, INC. | $257.17 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $209.91 | 2025 | Eylea Hd |
| Alcon Vision LLC | $145.49 | 2021-2024 | Clareon |
| Bausch & Lomb Americas INC. | $116.13 | 2022 | |
| Biotissue Holdings INC. | $58.31 | 2023-2024 | |
| Tarsus Pharmaceuticals, INC. | $41.50 | 2025 | Xdemvy |
| Abbvie INC. | $36.18 | 2022-2023 | |
| Argenx US, INC. | $33.27 | 2025 | Vyvgart Hytrulo |
| Kowa Pharmaceuticals America, INC. | $24.73 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $21.12 | 2024 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $17.08 | 2023 | Puraply |
| Rayner Intraocular Lenses Limited | $14.11 | 2025 | Omidria |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Ramey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.